Format

Send to

Choose Destination
Oncogene. 2014 Jan 2;33(1):1-9. doi: 10.1038/onc.2013.34. Epub 2013 Feb 18.

Targeted therapy for melanoma: rational combinatorial approaches.

Author information

1
Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
2
1] Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA [2] Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Abstract

The treatment of melanoma, the most aggressive form of skin cancer, is being revolutionized by the development of personalized targeted therapy approaches. Mutant-selective BRAF inhibitors and MEK inhibitors have demonstrated impressive clinical results in molecularly selected patients. However, emerging understanding of the molecular heterogeneity of this disease and the identification of multiple mechanisms of resistance to targeted therapies strongly support the rationale for combinatorial approaches. In this review, we will discuss the preclinical and clinical studies that are testing leading hypotheses and emerging combinatorial strategies for the future.

PMID:
23416974
DOI:
10.1038/onc.2013.34
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center